Hematologic Oncology

The FDA has extended the PDUFA action date to July 6, 2026, for approving Orca-T across different hematologic malignancies.

The real-world CHRONOS study may set a new benchmark for the third-line management of acute graft-vs-host-disease with gastrointestinal involvement.

A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

An intern doctor at Al-Sabah Children’s Hospital sheds light on health care delivery gaps in a resource-limited setting.

Maintaining quality of life should be a key focus in the treatment of different hematologic malignancy populations, explained Guenther Koehne, MD.

The FDA has set a Prescription Drug User Fee Act date for the third quarter of 2026 for approving rusfertide for polycythemia vera.

Although AI can be effective in hematologic malignancies and palliative care, it must be used ethically, said Ram Prakash Thirugnanasambandam, MBBS.

Findings presented at the 2026 Tandem Meetings showed that an accelerated immune constitution of donor-derived CD4-positive T cells was observed with TRX103.

Safety-optimized CAR-T platforms and supportive-care breakthroughs highlight a maturing field focused on access, durability, and real-world implementation.

Data from the phase 1/2 CADENZA trial support pivekimab sunirine as a potential standard treatment for this rare blood cancer population.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

Researchers have generated a high-resolution spatial atlas of the human gastrointestinal tract in aGVHD, revealing epithelial disruption and unexpected immune cell patterns that reshape how the disease is understood.

Investigators are currently evaluating zavabresib plus ruxolitinib among patients with myelofibrosis in the phase 1 PROMise study.

The FDA has assigned a PDUFA date of August 30, 2026, for approving ropeginterferon alfa-2b-njft among adults with essential thrombocytopenia.

Patients with BPDCN who did not achieve a complete or clinical complete response during treatment experienced a restoration of hematopoiesis.

The FDA no longer considers the phase 3 ALLELE trial adequate to support the approval of tabelecleucel for patients with EBV-positive PTLD.

Prior data from the 2025 ASH meeting showed that CK0804 may complement JAK inhibition among patients with myelofibrosis.

Results from the phase 3 VERIFY and phase 2 REVIVE studies supported the NDA submission of the for rusfertide in this PV patient population.

Preclinical data from the phase 2 SUMMIT trial presented at the 2025 ASH meeting support the submission for bezuclastinib in this patient group.

An investigational new drug application for ALA-101 has been submitted to the FDA for the treatment of CD19-positive non-Hodgkin lymphoma and leukemia.

Nuvisertib combined with momelotinib achieved a spleen volume reduction of 25% at week 24 and any given time in 50% of patients with relapsed/refractory myelofibrosis.

Key presentations from the 2025 ASH meeting revealed potential therapeutic advances across leukemia, multiple myeloma, and lymphoma.

Across all dose levels of axatilimab, the 46-month OS rate was the 74.1% among patients with previously treated chronic graft-vs-host disease.

The FDA has given a PDUFA date of April 8, 2026, to the nivolumab/AVD regimen for stage III or IV classical Hodgkin lymphoma.

The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.